Related Experiment Video
Updated: Jun 11, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
The anticholinergic medication index and dementia risk: evidence from the UK Biobank and All of Us research program
Innocent Gerald Asiimwe1,2, Kate Best3, Reecha Sofat1
1Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Introduction:
Anticholinergic drugs are associated with adverse effects, including cognitive decline. In this study, we externally validated the Anticholinergic Medication Index (ACMI) by investigating the association between baseline anticholinergic burden and dementia risk in two large prospective cohorts: the UK Biobank (UKB) and the US All of Us (AoU) program.
Methods:
We analysed data from the UKB (n = 125 260; study period, 2000-15) and AoU (92 047; 2000-22). Cox proportional hazards models, adjusted for clinical and genetic covariates with death as a competing risk, assessed the association between baseline annual ACMI-computed anticholinergic burden and dementia risk. Exploratory genetic analyses included candidate gene analysis of acetylcholine signalling pathway genes in the UKB and development of a polygenic hazard score in AoU.
Results:
Prescription of any of the 88 ACMI-listed drugs at baseline was associated with increased dementia risk (UKB HR: 1.15, 95% CI 1.09-1.21; AoU: 1.06, 1.04-1.09) and mortality (UKB: 1.23, 1.19-1.27; AoU: 1.16, 1.13-1.19). We replicated the genetic influence of APOE on dementia risk (UKB [APOE ε4 vs ε3 carriers] HR: 2.05, 1.86-2.26; AoU: 1.61, 1.44-1.80). No significant gene-drug interactions were identified.
Conclusion:
Higher baseline ACMI scores were associated with increased risks of dementia and mortality in two large cohorts, providing external validation of the ACMI. While causal inference is not possible, these findings support the ACMI's potential utility as a prognostic tool for risk stratification and for informing future work on safer prescribing.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Drug Dosing: Geriatric Patients
Pharmacodynamics in Geriatric Patients: Effects of Age
Dementia
The progression of dementia is generally gradual.